- Report
- January 2024
- 80 Pages
Russia
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
Saudi Arabia
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
South Korea
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
United States
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
Vietnam
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
Poland
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
Argentina
From €1432EUR$1,500USD£1,199GBP
- Report
- June 2023
- 243 Pages
Global
From €3407EUR$3,570USD£2,855GBP
The Retinal Biologics market is a subset of the larger Biotechnology industry. It focuses on the development of treatments for retinal diseases, such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. These treatments are typically delivered through injections, implants, or other delivery systems. The goal of these treatments is to improve vision and reduce the risk of vision loss.
The Retinal Biologics market is highly competitive, with many companies developing innovative treatments. Companies in this market include Regeneron Pharmaceuticals, Allergan, Novartis, Genentech, and Roche. These companies are actively researching and developing treatments for retinal diseases, with the goal of improving patient outcomes. Show Less Read more